TG Therapeutics
TGTX
145 hedge funds and large institutions have $639M invested in TG Therapeutics in 2020 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 45 increasing their positions, 46 reducing their positions, and 20 closing their positions.
384% more call options, than puts
Call options by funds: $40.5M | Put options by funds: $8.37M
70% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 20
7% more funds holding
Funds holding: 135 → 145 (+10)
0.78% more ownership
Funds ownership: 58.45% → 59.23% (+0.78%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $646M → $639M (-$7.26M)
2% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$98.1M |
| 2 |
EP
Eversept Partners
New York
|
+$21.3M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$15.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$15.1M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$11.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$36.4M |
| 2 |
Millennium Management
New York
|
-$25.4M |
| 3 |
BM
Bridger Management
New York
|
-$13.4M |
| 4 |
Renaissance Technologies
New York
|
-$8.43M |
| 5 |
D.E. Shaw & Co
New York
|
-$7.63M |
TGTX Hedge Fund Activity: Q1 2020 in Review
145 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2020, worth a combined $639M — down 1.1% from $646M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new TGTX positions and 20 closed out — a net gain of 14 holders — while 45 added to existing stakes and 46 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $98.1M. The largest seller was Great Point Partners, cutting an estimated $36.4M.
- 145 institutional investors held TG Therapeutics (TGTX) as of Q1 2020, up from 135 in Q4 2019.
- Funds reported $639M of TG Therapeutics stock for Q1 2020, down 1.1% quarter-over-quarter.
- 34 funds opened new TG Therapeutics positions in Q1 2020 and 20 closed out, a net change of +14 holders.
- The largest TG Therapeutics buyer in Q1 2020 was Fidelity Investments, an estimated $98.1M added.
- The largest TG Therapeutics seller in Q1 2020 was Great Point Partners, an estimated $36.4M sold.
Based on aggregated 13F filings for Q1 2020.